Mesoblast (NASDAQ: MESO) leverages RYONCIL cash flow to fund major Phase 3 cell therapy programs
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Mesoblast Limited highlights progress as a global leader in allogeneic, off‑the‑shelf cellular medicines. Its first FDA‑approved product RYONCIL has generated net revenue exceeding US$100M since launch, with Q3 FY26 gross revenue of US$35M and net revenue of US$30M.
RYONCIL produced gross profit of US$44M in 1H FY26, against direct selling costs of US$7M. Net operating cash spend in Q3 FY26 was US$4M, supported by receipts of US$34.6M, and cash was US$122M at March 31, 2026. A new US$125M term loan replaces higher‑cost debt.
The company is funding an extensive pipeline, including Phase 3 programs for chronic low back pain and chronic heart failure using rexlemestrocel‑L, and label‑extension studies for RYONCIL in adult steroid‑refractory acute graft versus host disease and pediatric Duchenne muscular dystrophy. Mesoblast is also advancing next‑generation gene‑modified MSC platforms such as CAR‑MSCs and OV‑MSCs for new indications.
Positive
- None.
Negative
- None.
Insights
Mesoblast couples first product profitability with a capital-backed late-stage pipeline.
Mesoblast presents RYONCIL as a commercially validated allogeneic cell therapy, with net revenue above US$100M since launch and strong gross profit in 1H FY26. This single product is described as highly profitable on a stand‑alone basis, helping support broader development activities.
Operating cash burn in Q3 FY26 was limited to US$4M, aided by US$34.6M of receipts, while cash totaled US$122M at March 31, 2026. A new US$125M term loan replaces higher‑cost debt, suggesting a focus on lowering financing costs while funding R&D, manufacturing for Biologics License Applications, and commercial inventory.
The disclosed Phase 3 programs in chronic low back pain and heart failure, plus label expansions for RYONCIL, target total addressable markets in the multi‑billion‑dollar range. Actual outcomes will depend on clinical trial results, regulatory approvals, and execution of commercialization strategies described in the presentation.
Key Figures
RYONCIL cumulative net revenue: US$100M+
Q3 FY26 RYONCIL gross revenue: US$35M
Q3 FY26 RYONCIL net revenue: US$30M
+5 more
8 metrics
RYONCIL cumulative net revenue
US$100M+
Since product launch last year
Q3 FY26 RYONCIL gross revenue
US$35M
Quarterly product gross revenue
Q3 FY26 RYONCIL net revenue
US$30M
Quarterly product net revenue
1H FY26 RYONCIL gross profit
US$44M
Excluding amortization expense
1H FY26 direct selling costs
US$7M
Direct selling costs for RYONCIL
Q3 FY26 net operating cash spend
US$4M
Net operating cash spend in the quarter
Cash balance
US$122M
As of March 31, 2026
New term loan
US$125M
Replaces existing higher‑cost debt
Key Terms
Biologics License Application, steroid-refractory acute graft versus host disease, Phase 3 trial, chronic low back pain, +2 more
6 terms
Biologics License Application regulatory
"Operating plan includes spend on Phase 3 programs, manufacturing for BLA filing and commercial inventory"
A biologics license application is a formal request submitted to regulatory authorities seeking approval to market a new biological medicine, such as vaccines or treatments made from living organisms. It is a comprehensive review process that evaluates the safety, effectiveness, and manufacturing quality of the product. For investors, receiving approval signals that a biological therapy can be sold to the public, potentially leading to revenue growth and market success.
steroid-refractory acute graft versus host disease medical
"Focuses on increasing penetration of pediatric SR-aGvHD market and adult SR-aGvHD trial"
An aggressive complication after an allogeneic stem cell or bone marrow transplant where donor immune cells attack the patient’s organs and tissues, and that does not improve after standard high‑dose steroid treatment. Investors should care because it signals a high unmet medical need, often requires additional therapies, longer hospital stays and complex clinical trials, and therefore drives demand, pricing and regulatory attention for new treatments.
Phase 3 trial medical
"Phase 3 programs position rexlemestrocel-L to transform the treatment of low back pain and inflammatory heart failure"
A Phase 3 trial is a large, late-stage test of a new drug or medical treatment done on many people to make sure it really works and is safe. For investors, it matters because a successful Phase 3 usually means the company can ask regulators to sell the product and could earn lots of money, while failure can sharply reduce the company’s value.
chronic low back pain medical
"Phase 3 programs position rexlemestrocel-L to transform the treatment of low back pain with degenerative disc disease"
term loan financial
"New term loan totaling US$125M replaces existing higher-cost debt"
A term loan is a type of loan that is borrowed for a set period of time, with a fixed schedule for repaying the money, usually in regular payments. It matters to investors because it represents a company's borrowing costs and financial stability; reliable repayment of these loans can indicate strong financial health, while difficulties may signal potential risks.
allogeneic (off-the-shelf) cellular medicines technical
"World leader in developing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions"
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934
For the month of June 2026
Commission File Number 001-37626
Mesoblast Limited
(Exact name of Registrant as specified in its charter)
Not Applicable
(Translation of Registrant’s name into English)
Australia
(Jurisdiction of incorporation or organization)
(Jurisdiction of incorporation or organization)
Silviu Itescu
Chief Executive Officer and Executive Director
Level 38
55 Collins Street
Melbourne 3000
Australia
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F:
Form 20-F ☑ Form 40-F ☐
INFORMATION CONTAINED ON THIS REPORT ON FORM 6-K
On June 2, 2026, Mesoblast Limited filed with the Australian Securities Exchange an ASX CEO Connect presentation, which is attached hereto as Exhibit 99.1, and is incorporated herein by reference.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly organized.
Mesoblast Limited | ||||||||||||||
| /s/ Paul Hughes | ||||||||||||||
| Paul Hughes | ||||||||||||||
| Company Secretary | ||||||||||||||
Dated: June 10, 2026
INDEX TO EXHIBITS
| Item | ||||||||
99.1 | ASX CEO Connect Presentation of Mesoblast Ltd, dated June 2, 2026. | |||||||
1 June 2026 | ASX: MSB; Nasdaq: MESO ASX CEO Connect Presentation 1 Exhibit 99.1
2 This presentation includes forward-looking statements and forecasts that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward- looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this presentation are forward-looking statements. Words such as, but not limited to, “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” “targets,” “likely,” “will,” “would,” “could,” and similar expressions or phrases identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and future events , recent changes in regulatory laws, and financial trends that we believe may affect our financial condition, results of operation, business strategy and financial needs. These statements may relate to, but are not limited to: expectations with respect to sales and revenue, expectations regarding the safety or efficacy of, or potential applications for, Mesoblast's adult stem cell technologies; expectations regarding the strength of Mesoblast's intellectual property, the timeline for Mesoblast's regulatory approval process, and the scalability and efficiency of manufacturing processes; expectations about Mesoblast's ability to grow its business and statements regarding its relationships with current and potential future business partners and future benefits of those relationships; statements concerning Mesoblast's share price or potential market capitalization; and statements concerning Mesoblast's capital requirements and ability to raise future capital, among others. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. You should read this presentation together with our financial statements and the notes related thereto, as well as the risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast's actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, include, without limitation: risks inherent in the development and commercialization of potential products; uncertainty of clinical trial results or regulatory approvals or clearances; government regulation; the need for future capital; dependence upon collaborators; and protection of our intellectual property rights, among others. Accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise. Cautionary Note Regarding Forward Looking Statements
3 Mesoblast: Global Leader in Allogeneic (Off-the-Shelf) Cellular Medicines First FDA approval more than 1,100 patents & applications Robust Pipeline • World leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life- threatening inflammatory conditions • Locations in United States, Australia, and Singapore • Listed on NASDAQ (MESO) and ASX (MSB) • Developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L stromal cell technology platforms • First FDA-approved product launched successfully • Extensive global intellectual property portfolio with protection extending through to at least 2044 in all major markets • FDA-inspected commercial scale manufacturing process and facilities THREE Additional Major Phase 3 Assets
4 Mesoblast First-In-Class Leader in Allogeneic Cellular Therapies Ryoncil® Only FDA Approved MSC, Successful First US Launch Net revenue has exceeded US$100M since launch last year Highly profitable single product on stand-alone basis Proceeds from revenue generated is being re-invested in label extensions studies and blockbuster opportunities Pipeline with Multiple Blockbuster Opportunities Phase 3 programs position rexlemestrocel-L to transform the treatment of low back pain with degenerative disc disease, and inflammatory heart failure Phase 3 programs to extend Ryoncil® label to adult aGvHD and pediatric rare diseases such as Duchenne Muscular Dystrophy Commercial Capability Established Infrastructure to support product launches across multiple expansion indications Built specialized sales team focused on hospitals, transplant centers, and specialists
5 Mesenchymal Precursor / Stromal Cells Orchestrate Potent Anti-Inflammatory Cascade Activation Via Multiple Surface Receptors Results In Powerful Multi-Modal Response That Cannot Be Achieved By Agents Targeting Single Pathways Source: data on file Effector B cell M2 Breg Treg I n f l amma t i o n NK Activation Cytotoxicity Maturation Activation Antigen Presentation Proliferation Antibody production IDO, PGE2 TGF𝛽, M-CSF, CCL2 IL-10 TH17 Proliferation Cytokine secretion Cytotoxicity IL-10 TH1 M1 Immature DC IL-1 IL-6 TNFα IL-10 Mesenchymal Precursor / Stromal Cell Polarize M1 to M2
6 Advantages of Mesoblast’s Proprietary Cell Technology Provides Significant Barriers to Entry in End-to-End Supply Chain • No expression of cell surface co-stimulatory molecules • Do not induce immune reaction, no need for immunosuppression • Validated potency assays ensure batch-to- batch consistency • Proprietary media formulations and bioreactors for scale-up • A single donor ultimately supplies 1000’s of vials • Generation 2 process ~6x greater output/unit time. • Increasing yield / decreasing COGS Scalable Production Unique Off-the-Shelf (Allogeneic) Properties Cutting Edge & Patented Know-How Compelling Value Proposition • Scalable “off-the-shelf” cellular platforms • Expansion without differentiation
7 Mesoblast Allogeneic Mesenchymal Stromal Cell Portfolio Product Indication Phase 2 Phase 3 Approved RYONCIL® remestemcel-L Pediatric SR-aGvHD Adult SR-aGvHD RYONCIL® remestemcel-L Duchenne’s REVASCOR® rexlemestrocel-L (STRO3+) Adult HFrEF Class II/III Adult HFrEF End-stage Rexlemestrocel-L (STRO3+) CLBP SR-aGvHD = Steroid-Refractory Acute Graft versus Host Disease; HFrEF = Heart Failure with Reduced Ejection Fraction; CLBP = Chronic Low Back Pain This chart is figurative and does not purport to show individual trial progress within a clinical program Notes: ▪ JCR Pharmaceuticals Co., Ltd. (JCR), has the right to develop mesenchymal stromal cells (MSCs) in certain fields for the Japanese market, including for the treatment of hematological malignancies, such as Graft vs Host Disease, and for hypoxic ischemic encephalopathy (HIE). ▪ Grünenthal has an exclusive license to develop and commercialize rexlemestrocel-L for chronic low back pain in Europe and Latin America/Caribbean. ▪ Tasly Pharmaceuticals has exclusive rights for rexlemestrocel-L for the treatment or prevention of chronic heart failure in China. TAM ~US$1B TAM >US$1B TAM >US$1B TAM >US$10B TAM >US$10B
8 RYONCIL Profitability to Fund Growth Pipeline Successful U.S. commercial launch of RYONCIL • Q3 FY26 gross revenue US$35.3M, net revenue US$30.3M • RYONCIL gross profit 1H FY26, excluding amortization expense, was US$44.2M. Direct selling costs were US$7.7M Strong operating performance in the period allowed us to invest in: • R&D, including to support the Phase 3 trial on the blockbuster chronic low back pain indication • Clinical programs for lifecycle extension • Commercial manufacturing of Ryoncil® inventory as well as for launch of second- generation product
9 ➢ Mesoblast is leveraging the only FDA-approved MSC platform to create genetically-modified next gen products ➢ Enhanced (a) potency via payload ( ) or triggered pathway ( ), and (b) targeting via antigen binding moiety ( ) ➢ Two proprietary next gen platforms (patents through 2043) • Chimeric Antigen Receptor “CAR-MSCs” developed at Mayo Clinic* • Oncolytic Virus “OV-MSCs” developed at Baylor College of Medicine** ➢ IND-enabling development ongoing at each location Next Generation Gene Modified MSCs – Enhanced Products for New Indications *Nat Biomed Eng. 2024 April ; 8(4): 443–460. doi:10.1038/s41551-024-01195-6;**https://pubmed.ncbi.nlm.nih.gov/36989357
10 CAR-MSC Platform • Leverage tech behind CAR-T therapies without issues re: (i) safety and (ii) manufacturing • Broad range of potential target antigens/intracellular pathway choices - plug and play system • Enhanced targeting/increased potency can reduce dosing/COGS for all future indications • Lead products target Lupus and UC/Crohn’s, significant/unmet medical needs Antigen/Product Target Tissue Potential Indication(s) Triggered Intracellular Pathway CD19-CAR-MSC CD19 B Cells Lupus CD28z, TLR3, TLR4, CD28, IFNy ECAD-CAR-MSC Inflamed tissue UC/Crohn’s MOG-CAR-MSC Myelin Sheath MS COL2A1-CAR-MSC Collagen RA AMPA-CAR-MSC Neurons Alzheimer's CAR-MSC-CCN1 Skin Wounds (A) Chimeric antigen receptor (CAR) targeting specific disease-associated antigen (B) Binding to antigen triggers selected intracellular pathway to enhance potency (C) Retain native properties of MSCs (A) (B) (C)
11 Strong Financial Position • RYONCIL net revenue exceeded US$100 million since launch last year • Net operating cash spend for Q3 FY26 was US$4.1M • The reduction in net operating cash spend was driven by receipts of US$34.6 million and tight control of operating expenses • Cost discipline approach to managing spend in-line with revenue • Operating plan includes spend on Phase 3 programs, manufacturing for BLA filing and commercial inventory • New term loan totaling US$125M replaces existing higher- cost debt Cash balance US$122M at Mar 31, 2026 BLA: Biologics License Application (FDA)
12 Anticipated Major Upcoming Milestones RYONCIL Commercial • Net revenue has exceeded US$100M since launch • Strategy in place to strongly grow revenue base • Focused on increasing penetration of pediatric SR-aGvHD market Label extension • Funded by RYONCIL revenues • Adult SR-aGvHD with BMT-CTN network, trial initiated, to complete in 12-18 months • Pediatric Duchenne’s Phase 3 IND cleared by FDA SR-aGvHD: steroid-refractory acute graft versus host disease | BMT-CTN: Blood and Marrow Transplant Clinical Trials Network | IND: Investigational New Drug | BLA: Biologics License Application | LVAD: left ventricular assist device | HFrEF: heart failure reduced ejection fraction | NYHA: New York Heart Association Rexlemestrocel-L Blockbuster Programs Chronic low back pain (CLBP) • Achieved patient recruitment target in pivotal Phase 3 trial in April • Top-line primary endpoint mid-CY2027 • BLA filing for FDA approval Chronic heart failure (CHF) • File BLA with FDA for end-stage heart failure patients on LVADs • Will facilitate label-extension in NYHA II/III HFrEF with opportunity for strategic partnership
13 Thank You
FAQ
How much revenue has Mesoblast (MESO) generated from RYONCIL so far?
RYONCIL net revenue has exceeded US$100 million since its launch last year. In Q3 FY26 alone, the product delivered gross revenue of US$35 million and net revenue of US$30 million, underpinning Mesoblast’s investment in further clinical programs.
What is Mesoblast’s cash position and recent cash burn as of March 2026?
Mesoblast reported a cash balance of US$122 million as of March 31, 2026. Net operating cash spend for Q3 FY26 was US$4 million, supported by US$34.6 million in receipts and ongoing cost discipline aligned with revenue.
Which late-stage clinical programs is Mesoblast (MESO) prioritizing?
Mesoblast is prioritizing Phase 3 programs for chronic low back pain using rexlemestrocel‑L and heart failure indications, including end‑stage patients on LVADs. It is also pursuing label extensions for RYONCIL in adult SR‑aGvHD and pediatric Duchenne muscular dystrophy.
What upcoming milestones did Mesoblast outline for its chronic low back pain program?
Mesoblast has achieved the patient recruitment target in its pivotal Phase 3 chronic low back pain trial. The company anticipates a top‑line primary endpoint readout in mid‑calendar 2027, followed by a planned BLA filing in the United States for FDA approval.
How is Mesoblast funding its growth and clinical pipeline?
Growth is being funded primarily by RYONCIL revenues and new financing. RYONCIL generated net revenue above US$100 million, while a new US$125 million term loan replaced higher‑cost debt, supporting Phase 3 trials, manufacturing for BLAs, and commercial inventory.
What next-generation cell therapy platforms is Mesoblast developing?
Mesoblast is developing CAR‑MSCs and OV‑MSCs, genetically modified mesenchymal stromal cell platforms. These aim to enhance potency and targeting for diseases such as lupus, inflammatory bowel disease, and other indications, with IND‑enabling work underway at partner institutions.